Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To determine the ORR of dabrafenib and trametinib anti-cancer combination therapy in subjects with selected rare BRAF V600E mutated solid tumors or hematologic malignancies.
Inclusion criteria
- Mutations of BRAF V600E have been identified at a high frequency in melanoma, PTC, colorectal and ovarian cancers. Such mutations have also been reported in some rare cancers such as
- anaplastic thyroid cancer, hairy cell leukemia, gastrointestinal stromal tumors, non-seminomatous/non-geminomatous germ cell tumors, biliary tract cancer, multiple myeloma, adenocarcinoma of the small intestine, World Health Organization Grade 1 and 2 gliomas and WHO Grade 3 and 4 gliomas